470 related articles for article (PubMed ID: 27048211)
21. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
[TBL] [Abstract][Full Text] [Related]
22. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
23. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
Dobashi A
J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.
Nagakita K; Takata K; Taniguchi K; Miyata-Takata T; Sato Y; Tari A; Ohnishi N; Noujima-Harada M; Omote S; Nakamura N; Iwamuro M; Maeda Y; Okada H; Tanimoto M; Yoshino T
Pathol Int; 2016 Aug; 66(8):444-52. PubMed ID: 27439595
[TBL] [Abstract][Full Text] [Related]
26. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
[TBL] [Abstract][Full Text] [Related]
27. Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.
Frauenfeld L; Castrejon-de-Anta N; Ramis-Zaldivar JE; Streich S; Salmerón-Villalobos J; Otto F; Mayer AK; Steinhilber J; Pinyol M; Mankel B; Ramsower C; Bonzheim I; Fend F; Rimsza LM; Salaverria I; Campo E; Balagué O; Quintanilla-Martinez L
Blood Adv; 2022 Apr; 6(7):2361-2372. PubMed ID: 34654055
[TBL] [Abstract][Full Text] [Related]
28. Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R; Hansen J; Pelzer BW; Nieper P; Lohmann T; Kisis I; Riet T; Kohlhas V; Nguyen PH; Peifer M; Abedpour N; Bosco G; Thomas RK; Kochanek M; Knüfer J; Jonigkeit L; Beleggia F; Holzem A; Büttner R; Lohneis P; Meinel J; Ortmann M; Persigehl T; Hallek M; Calado DP; Chmielewski M; Klein S; Göthert JR; Chapuy B; Zevnik B; Wunderlich FT; von Tresckow B; Jachimowicz RD; Melnick AM; Reinhardt HC; Knittel G
Blood Cancer Discov; 2023 Jan; 4(1):78-97. PubMed ID: 36346827
[TBL] [Abstract][Full Text] [Related]
29. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
30. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
31. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
32. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
[TBL] [Abstract][Full Text] [Related]
33. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
34. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
[TBL] [Abstract][Full Text] [Related]
37. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
38. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
[TBL] [Abstract][Full Text] [Related]
39. Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12.
Nagao T; Yoshifuji K; Sadato D; Motomura Y; Saito M; Yamamoto K; Yamamoto K; Nogami A
Exp Hematol; 2022 Dec; 116():37-49. PubMed ID: 36191884
[TBL] [Abstract][Full Text] [Related]
40. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
